MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients
Annals of Hematology · 2024-10 · 103 (10) · 4065-4077
DOI: 10.1007/s00277-024-05908-4 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, online erschienen am 29.07.2024. Verfasst von Stefanie Jilg und 15 weiteren Autor:innen. Beteiligte Einrichtung: Onkologie Erding, Bajuwarenstr.3, Erding, Germany. stefanie.jilg@onkologie-erding.de. Hauptthemen laut MEDLINE: Primary Myelofibrosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Onkologie Erding, Bajuwarenstr.3, Erding, Germany. stefanie.jilg@onkologie-erding.de.
- Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. stefanie.jilg@onkologie-erding.de.
- Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
- Medical Clinic and Policlinic I, University Hospital Dresden, TU Dresden, Dresden, Germany.
- Abteilung Hämatologie und Internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
- Department of Hematology and Oncology, University Hospital Erlangen, Friedrich- Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
ORCID-Profile: Stefanie Jilg, Madlen Jentzsch, Florian Heidel, Petro E Petrides
Zitieren
APA
Jilg, S., Schwaab, J., Sockel, K., Crodel, C. C., Brueckl, V., Stegelmann, F., Jentzsch, M., Sasca, D., Moyses, M., Fuhrmann, S., Gundel, D., Caduc, M., Teichmann, L. L., Heidel, F., Al-Ali, H. K., & Petrides, P. E. (2024). MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients. Annals of Hematology, 103(10), 4065-4077. https://doi.org/10.1007/s00277-024-05908-4
Vancouver
Jilg S, Schwaab J, Sockel K, Crodel CC, Brueckl V, Stegelmann F, et al. MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients. Annals of Hematology. 2024;103(10):4065-4077. doi:10.1007/s00277-024-05908-4
BibTeX
@article{Jilg2024,
author = {Jilg, Stefanie and Schwaab, Juliana and Sockel, Katja and Crodel, Carl C and Brueckl, Valeska and Stegelmann, Frank and Jentzsch, Madlen and Sasca, Daniel and Moyses, Margarete and Fuhrmann, Stephan and Gundel, Daniel and Caduc, Madlen and Teichmann, Lino L and Heidel, Florian and Al-Ali, Haifa K and Petrides, Petro E},
title = {MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients},
journal = {Annals of Hematology},
year = {2024},
volume = {103},
number = {10},
pages = {4065--4077},
doi = {10.1007/s00277-024-05908-4}
}
EUVIMED